dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Cortellini, Alessio |
dc.contributor.author | Dettorre, Gino M |
dc.contributor.author | Dafni, U. |
dc.contributor.author | Aguilar Company, Juan |
dc.contributor.author | Castelo-Branco, L. |
dc.contributor.author | Lambertini, Matteo |
dc.date.accessioned | 2022-12-09T09:10:57Z |
dc.date.available | 2022-12-09T09:10:57Z |
dc.date.issued | 2022-11 |
dc.identifier.citation | Cortellini A, Dettorre GM, Dafni U, Aguilar-Company J, Castelo-Branco L, Lambertini M, et al. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries. J Immunother Cancer. 2022 Nov;10(11):e005732. |
dc.identifier.issn | 2051-1426 |
dc.identifier.uri | https://hdl.handle.net/11351/8618 |
dc.description | COVID-19; Immunogenicitat; Vacuna |
dc.description.sponsorship | OnCovid is sponsored by Imperial College London and received direct project funding and infrastructural support by the NIHR Imperial Biomedical Research Centre (BRC). |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | Journal for ImmunoTherapy of Cancer;10(11) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) |
dc.subject | Immunoteràpia |
dc.subject | Càncer - Tractament |
dc.subject.mesh | Immunotherapy |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Coronavirus Infections |
dc.title | Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/jitc-2022-005732 |
dc.subject.decs | inmunoterapia |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | infecciones por Coronavirus |
dc.relation.publishversion | http://dx.doi.org/10.1136/jitc-2022-005732 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Cortellini A] Department of Surgery & Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK. Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy. [Dettorre GM] Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. [Dafni U] Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece. [Aguilar-Company J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Castelo-Branco L] Scientific and Medical Division, ESMO (European Society for Medical Oncology), Lugano, Switzerland. NOVA National School of Publich Health, NOVA University, Lisbon, Portugal. [Lambertini M] Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genova, Italy. Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy |
dc.identifier.pmid | 36450384 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |